83 related articles for article (PubMed ID: 1881678)
21. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.
Kumar MS; Lakshmi V; Rajagopalan R
Indian J Med Microbiol; 2006 Jul; 24(3):208-11. PubMed ID: 16912442
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae.
Hope R; Potz NA; Warner M; Fagan EJ; Arnold E; Livermore DM
J Antimicrob Chemother; 2007 Jan; 59(1):110-3. PubMed ID: 17090552
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases.
Sanders CC
J Chemother; 1996 Feb; 8 Suppl 2():57-62. PubMed ID: 8738847
[TBL] [Abstract][Full Text] [Related]
24. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
[TBL] [Abstract][Full Text] [Related]
25. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins.
Betriu C; Salso S; Sánchez A; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
Int J Antimicrob Agents; 2006 Jul; 28(1):1-5. PubMed ID: 16769202
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
Lim VK; Halijah MY
Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
[TBL] [Abstract][Full Text] [Related]
29. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
30. Comparative activity of ceftazidime and four other cephalosporins against gram-negative bacteria and their sensitivity to beta-lactamases.
Galante D; Esposito S; Barba D; Pennucci C; Limauro D; Scioli C
Chemioterapia; 1984 Aug; 3(4):250-4. PubMed ID: 6398123
[TBL] [Abstract][Full Text] [Related]
31. [Monitoring of bacteria resistance in burn patients].
Zhang M; Xu X; Liao P
Zhonghua Wai Ke Za Zhi; 1999 May; 37(5):278-81. PubMed ID: 11829839
[TBL] [Abstract][Full Text] [Related]
32. [Antibiotic activity and synergism of ceftazidime and netilmicin against gram-negative pathogenic bacteria].
Baumgärtner M; Müller HP; Wundt W
Arzneimittelforschung; 1983; 33(12):1615-9. PubMed ID: 6320836
[TBL] [Abstract][Full Text] [Related]
33. In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin.
Chin NX; Neu HC
Chemioterapia; 1987 Oct; 6(5):329-36. PubMed ID: 3322588
[TBL] [Abstract][Full Text] [Related]
34. Performance of a novel fluorogenic chimeric analog for the detection of third-generation cephalosporin resistant bacteria.
Park MJ; Park YJ; Oh EJ; Chang J; Kim Y; Yu J; Park KG; Ahn DR
J Microbiol Methods; 2016 Dec; 131():161-165. PubMed ID: 27784641
[TBL] [Abstract][Full Text] [Related]
35. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.
Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594
[TBL] [Abstract][Full Text] [Related]
36. Use of cefotaxime or ceftazidime susceptibility tests for predicting susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa.
Heym B; Lacroix O; Péan Y; Gertner J; Nicolas MH; Jarlier V
J Antimicrob Chemother; 1994 Apr; 33(4):729-35. PubMed ID: 8056691
[TBL] [Abstract][Full Text] [Related]
37. Cefotaxime, des-Cefotaxime and Ceftazidime: in vitro activity and stability to hydrolysis from TEM-derived extended spectrum beta-lactamases.
Segatore B; Franceschini N; Perilli M; Setacci D; Amicosante G
Infez Med; 2002 Mar; 10(1):16-20. PubMed ID: 12700436
[TBL] [Abstract][Full Text] [Related]
38. [Comparative antibacterial activity of cefotaxime, ceftazidime and cefepime with regard to different strains of Enterobacter aerogenes selected for their resistance to third generation cephalosporins].
Husson MO; Quelquejay J; Fruchart A; Izard D
Pathol Biol (Paris); 2000 Dec; 48(10):933-9. PubMed ID: 11204925
[TBL] [Abstract][Full Text] [Related]
39. Serum bactericidal activity against Enterobacteriaceae producing broad-spectrum beta-lactamases in volunteers administered ofloxacin and cefotaxime, alone or combined.
Weber P; Boussougant Y; Farinotti R; Carbon C
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):524-6. PubMed ID: 2504593
[TBL] [Abstract][Full Text] [Related]
40. Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.
Marone P; Navarra A; Monzillo V; Traverso A
Drugs Exp Clin Res; 1990; 16(12):629-33. PubMed ID: 2130005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
